Incorporation of PEI into a prostate specific membrane antigen (PSMA)-targeted nanoplatform with a poly-L-lysine backbone, carrying multimodality imaging reporters together with siRNA or cDNA and a prodrug enzyme for cancer theragnostic imaging, has been achieved (Chen et al., 2012; Chen et al., 2017a). This evidence concerns the gene FOLH1 and cancer.